索拉非尼治疗肝移植术后肝癌复发的疗效与肿瘤组织Ki-67表达及微血管密度的关系

摘要

AIM: To study the therapeutic effect of sorafenib on patients with tumor recurrence after liver transplantation and its relation with the expression of Ki - 67 and microvessel density( MVD ).METHODS: Thirty patients with tumor recurrence after liver transplantation were treated with sorafenib.The therapeutic effect of sorafenib was observed.The expression of Ki - 67 and CD34 in the tissue samples of liver cancer were examined by immunohistochemistry.The MVD was also calculated according to the expression of CD34.RESULTS: In 30 patients treated with sorafenib, none of them achieved complete response ( CR ), 13 achieved partial response ( PR ), 8 had stable disease ( SD ), and 9 had progressive disease ( PD ).The therapeutic effect of sorafenib was associated significantly with Ki - 67 expression.The mean counts of MVD were 356.45 ± 156.13 in PR patients, and 99.39 ±49.88 in PD patients.A significant difference of MVD between PR and PD patients was observed.CONCLUSION: There is a better therapeutic effect of sorafenib in treating tumor recurrence after liver transplantation in the patients with Ki - 67 - positive expression and high MVD.%目的:研究索拉非尼对肝移植术后肝癌复发的治疗效果与肿瘤组织Ki-67表达及微血管密度(MVD)的关系.方法:观察索拉非尼治疗肝移植术后肝癌复发30例的疗效;用免疫组化法检测Ki-67及CD34在肝癌组织中的表达,计算肿瘤MVD.结果:30例患者中,完全缓解(CR) 0例,部分缓解(PR) 13例,稳定(SD) 8例,进展(PD)9例.索拉非尼对肝移植术后肝癌复发的疗效与Ki-67表达阳性之间有显著正相关性.PR患者13例,MVD均数为356.45±156.13;SD患者8例,MVD均数为234.13±145.43;PD患者9例,MVD均数为99.39±49.88;PR与PD患者之间,MVD均值具有显著差异.结论:索拉非尼对肝移植术后肝癌复发有疗效.Ki-67阳性染色及MVD高的肝癌患者,肝移植术后肝癌复发使用索拉非尼治疗效果较好.